Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/TP.0000000000004182 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A serological test based on mutated recombinant Fasciola hepatica cathepsin L protease for the diagnosis of equine fasciolosis.
Vet Parasitol
September 2025
Medical Micro- & Molecular Biology, Institute of Chemistry and Biotechnology, Zurich University of Applied Sciences (ZHAW), Wädenswil, Switzerland; Precision Parasitology AG, Switzerland; Institute of Parasitology, Vetsuisse Faculty, University of Zurich, Zurich, Switzerland. Electronic address: ra
Fasciola hepatica is a common trematode parasite of livestock in many regions, causing significant economic losses and affecting animal welfare. Horses rarely develop patent liver fluke infection. However, liver damage can affect animal health and welfare.
View Article and Find Full Text PDFTranscriptional regulation of Ligase IV by an intronic regulatory element directs thymocyte development.
Genes Immun
September 2025
Department of Microbial Infection and Immunity, The Ohio State University, Columbus, OH, USA.
Double-strand breaks represent the most dangerous form of DNA damage, and in resting cells, these breaks are sealed via the non-homologous end joining (NHEJ) factor Ligase IV (LIG4). Excessive NHEJ may be genotoxic, necessitating multiple mechanisms to control NHEJ activity. However, a clear mechanism of transcriptional control for them has not yet been identified.
View Article and Find Full Text PDFSpatial and Functional Characterization of IL1RL1+ Mast Cells Reveals Immune Regulatory Roles in Renal Cancer.
Mol Cell Probes
September 2025
Department of Urology, The First Affiliated Hospital of Xinxiang Medical University, Weihui, Henan, 453100, China. Electronic address:
Background: Interleukin-1 receptor-like 1 (IL1RL1, also known as ST2) plays a critical role in immune regulation. Pan-cancer analysis has revealed that IL1RL1 is closely associated with cellular immune functions; however, its role in clear cell renal cell carcinoma (ccRCC) and the tumor microenvironment (TME) remains poorly defined.
Methods: We analyzed IL1RL1 expression patterns using data from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases.
MOG-IgG Frequency in Multiple Sclerosis: Diagnostic Challenges With Low-Titer Results.
Eur J Neurol
September 2025
Department of Neurology, Research Institute and Hospital of National Cancer Center, Goyang, Republic of Korea.
Background: Myelin oligodendrocyte glycoprotein immunoglobulin G (MOG-IgG) positivity has been reported in some people with multiple sclerosis (pwMS), posing a diagnostic challenge. However, most studies have been conducted in predominantly Caucasian populations. We aimed to determine the frequency of MOG-IgG in a large, predominantly Asian MS cohort using a validated MOG-IgG assay.
View Article and Find Full Text PDFAn Open-Label, Single-Arm, Phase II Trial of Sintilimab Plus Anlotinib for Metastatic Non-Small Cell Lung Cancer After First-Line PD-(L)1 Inhibitor.
Cancer Med
September 2025
Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, China.
Background: Although immune checkpoint inhibitors (ICIs) have markedly improved first-line management of non-small cell lung cancer (NSCLC), many tumors eventually escape control after anti-PD-(L)1 therapy, leaving a clear therapeutic gap. Preclinical studies and preliminary clinical data suggest that coupling ICIs with anti-angiogenesis therapy can yield complementary antitumor effects. Consequently, we launched this investigation to evaluate the therapeutic benefit and tolerability of sintilimab, a PD-(L)1-blocking monoclonal antibody, together with the oral multi-target anti-angiogenesis agent anlotinib in metastatic NSCLC individuals experiencing progression after first-line PD-(L)1 inhibition.
View Article and Find Full Text PDF